The global contraceptive drugs and devices market size accounted for USD 31.40 billion in 2024, grew to USD 33.26 billion in 2025 and is expected to be worth around USD 55.86 billion by 2034, registering a healthy CAGR of 5.93% between 2024 and 2034. The Asia Pacific contraceptive drugs and devices market size is evaluated at USD 10.99 billion in 2024 and is expected to grow at a CAGR of 6.07% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Contraceptive Drugs and Devices Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Contraceptive Drugs and Devices Market Revenue and Volume, By Product, 2024-2034
8.1.1 Contraceptive Drugs
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Contraceptive Devices
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Contraceptive Drugs and Devices Market Revenue and Volume, By Distribution Channels Outlook, 2024-2034
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Clinics
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Online Channels
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Public Channels & NGOs
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
9.1.6. Other
9.1.6.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.1.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.5.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Product (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, By Distribution Channels Outlook (2021-2034)
11.1. Abbvie, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Afaxys, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Agile Therapeutics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bayer AG
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. China Resources (Holdings) Co., Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Church & Dwight Co., Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Cupid Limited
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Helm AG
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Johnson & Johnson Services, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Organon Group of Companies
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample